Could Helping the Body Clear “Zombie Cells” Be Better Than Simply Killing Them?

Senescent cells can linger in ageing tissues and contribute to inflammation and disease. New research from Albert Einstein College of Medicine suggests that restoring a cellular recycling pathway may help the immune system clear these cells more effectively. The findings are promising—but the treatment has only been tested in preclinical research.

Key Benefits

Explains why senescent cells can accumulate with age.

Introduces chaperone-mediated autophagy (CMA), a specialised cellular recycling process.

Shows how researchers connected cellular recycling with immune-cell function.

Explains the potential relevance to lung fibrosis.

Separates mouse-study results from treatments proven in humans.

𝗧𝗛𝗘 𝗣𝗥𝗢𝗕𝗟𝗘𝗠 𝗪𝗜𝗧𝗛 “𝗭𝗢𝗠𝗕𝗜𝗘 𝗖𝗘𝗟𝗟𝗦”

Some cells reach a point where they stop dividing but refuse to disappear. Scientists call them senescent cells.

These cells are not always harmful. Senescence can help prevent damaged cells from multiplying and plays a role in normal processes such as wound healing. The problem arises when senescent cells persist and release inflammatory signals that can affect nearby tissue.

As these cells accumulate, researchers want to understand how the body can remove them without disrupting healthy functions.

𝗔 𝗗𝗜𝗙𝗙𝗘𝗥𝗘𝗡𝗧 𝗦𝗧𝗥𝗔𝗧𝗘𝗚𝗬: 𝗥𝗘𝗦𝗧𝗢𝗥𝗘 𝗖𝗘𝗟𝗟𝗨𝗟𝗔𝗥 𝗥𝗘𝗖𝗬𝗖𝗟𝗜𝗡𝗚

A study published in Nature Aging on October 5, 2026, led by researchers at Albert Einstein College of Medicine, investigated a process called chaperone-mediated autophagy, or CMA.

CMA is a specialised form of cellular recycling. It helps cells identify selected proteins and deliver them to lysosomes, where they are broken down.

The researchers found that declining CMA activity with age affected both senescent cells and macrophages—the immune cells that can engulf and remove unwanted material.

That creates a potential double problem: senescent cells develop more harmful characteristics, while some of the immune cells responsible for clearing them become less effective.

𝗪𝗛𝗔𝗧 𝗗𝗜𝗗 𝗧𝗛𝗘 𝗦𝗧𝗨𝗗𝗬 𝗙𝗜𝗡𝗗?

The team investigated a small-molecule compound called CA77.1, developed to activate CMA.

In aged mice, daily oral treatment over five months reduced senescent-cell accumulation in several organs and lowered signs of inflammation and fibrosis. In separate experiments, treatment improved the ability of macrophages isolated from aged mice to engulf material.

The researchers also examined lung tissue from people with idiopathic pulmonary fibrosis (IPF), a serious disease in which scar tissue builds up in the lungs. They found reduced CMA activity in these human samples.

That human-tissue finding matters because it suggests the pathway may be relevant to human disease. However, it does not show that CA77.1 works in people.

In a mouse model of lung fibrosis, treatment begun early after lung injury reduced fibrosis severity and markers associated with inflammation and cellular senescence. Timing mattered: the results were less pronounced when treatment began later.

𝗪𝗛𝗬 𝗧𝗛𝗜𝗦 𝗜𝗦 𝗡𝗢𝗧 𝗔𝗡 𝗔𝗡𝗧𝗜-𝗔𝗚𝗘𝗜𝗡𝗚 𝗧𝗥𝗘𝗔𝗧𝗠𝗘𝗡𝗧 𝗬𝗘𝗧

The study points to a possible alternative to approaches that aim to kill senescent cells directly: improve cellular maintenance and help immune cells remove them.

But mouse experiments cannot establish that a treatment is safe, effective or capable of extending healthy human lifespan. CA77.1 is not an established anti-ageing therapy, and these findings do not justify buying unproven supplements or attempting to manipulate CMA independently.

Researchers must still determine whether this approach can be developed into a safe treatment for people, which diseases it might help, and whether any benefits outweigh potential risks.

𝗠𝗘𝗡𝟯𝟱 𝗧𝗔𝗞𝗘𝗔𝗪𝗔𝗬

The interesting discovery is not simply that “zombie cells” may be harmful. It is that the body’s own recycling machinery and immune defences may work together to control them—and that ageing may weaken both sides of that relationship.

𝗕𝗢𝗧𝗧𝗢𝗠 𝗟𝗜𝗡𝗘

Helping the body clear senescent cells could become a valuable research direction. For now, the evidence is promising preclinical science, not a proven way to reverse ageing or treat lung fibrosis in humans.